申请人:Mascitti Vincent
公开号:US20120295845A1
公开(公告)日:2012-11-22
Compounds of formula (I) wherein: X is (A) or (B); Y is O or a bond; R
1
is —C(O)—O—R
3
or R
2
is hydrogen, cyano, C
1
-C
6
alkyl, or C
3
-C
6
cycloalkyl; R
5
is hydrogen, cyano, nitro, C
1
-C
6
fluoroalkyl, C
1
-C
6
alkyl, C
1
-C
6
alkoxy, fluoroalkoxy, or C
3
-C
6
cycloalkyl; R
6
is hydrogen, C
1
-C
6
alkyl, C
3
-C
6
cycloalkyl, —C(O)—NH
2
, or C
1
-C
6
alkyl substituted with hydroxy or C
1
-C
6
alkoxy; m is 1 or 2, wherein when m is 1 then R
8
is hydrogen, C
1
-C
6
alkyl, —CH
2
—(C
1
-C
5
)haloalkyl, C
3
-C
6
cycloalkyl, or C
1
-C
6
alkyl substituted with hydroxy; and when m is 2 then each R
8
is independently C
1
-C
3
alkyl or —CH
2
—(C
1
—C
2
)haloalkyl; modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.
式(I)的化合物,其中:X为(A)或(B); Y为氧或键;R1为—C(O)—O—R3或R2为氢、氰基、C1-C6烷基或C3-C6环烷基;R5为氢、氰基、硝基、C1-C6氟代烷基、C1-C6烷基、C1-C6烷氧基、氟代烷氧基或C3-C6环烷基;R6为氢、C1-C6烷基、C3-C6环烷基、—C(O)—NH2或C1-C6烷基取代的羟基或C1-C6烷氧基;m为1或2,其中当m为1时,R8为氢、C1-C6烷基、—CH2—(C1-C5)卤代烷基、C3-C6环烷基或C1-C6烷基取代的羟基;当m为2时,每个R8独立地为C1-C3烷基或—CH2—(C1-C2)卤代烷基;本文描述了这些化合物调节G蛋白偶联受体GPR119的活性及其在治疗与动物体内G蛋白偶联受体GPR119调节相关的疾病中的用途。